Human donor tissue revealed six spatial domains across an Alzheimer's disease continuum, as researchers combined spatial transcriptomics with single-nucleus RNA sequencing in superior frontal cortex from octogenarians and cognitively intact centenarians to map different microglial programs around an apparent shift from amyloid-associated inflammation toward tau-associated processes. [1][2]

The resilience patterns differed: octogenarians with amyloid but without dementia lacked a later antigen-presenting microglial program, while centenarians showed that program largely uncoupled from tau accumulation, suggesting more than one route by which brains can coexist with pathology without the same cognitive outcome. [1][2]

The primary Nature Medicine paper first appeared June 4, and July 26 was the date of a VIB explainer distributed by ScienceDaily, making the later event institutional publicity rather than a new experiment. [1][2]

Calling the pattern a tipping point is useful shorthand rather than a demonstrated clock, because postmortem tissue captures location and association after death but cannot by itself prove temporal order, a deterministic transition, a drug target or treatment efficacy.

Crossref reports that several authors work or worked for Muna Therapeutics and that senior authors disclosed consulting, ownership or other industry relationships; human tissue makes the map relevant to human disease, but cohort detail, replication, causal perturbation and target validation remain necessary before it can become a therapy. [2]

-- KENJI NAKAMURA, Tokyo